D eep brain stimulation is a now a commonly used procedure for addressing the motor symptoms and fluctuations in advanced PD. The most common surgical approach has been to simultaneously implant 2 DBS devices (one in each hemisphere).
1 Parkinson disease, however, is an asymmetrical process, and it has been observed that a number of patients have experienced great benefit from a single unilateral DBS lead. 5 A few studies have revealed that unilateral STN DBS has provided bilateral improvement. 3, 5 While the use of 2 leads may be more likely to result in cognitive impairment, The aim of this study was to examine the reasons underpinning the patients' decision-making process.
Prior to randomization, we hypothesized that unilateral stimulation would provide sufficient benefit and satisfaction in patients with more asymmetrical PD and thus, these patients would be more likely to voluntarily decline a contralateral DBS implantation. Additionally, we hypothesized that surgical site (GPi vs STN) and laterality (left vs right lead) would have no effect on the decision to remain with a single-sided DBS.
Methods
Fifty-two patients with PD were randomized to receive STN or alternatively GPi DBS as part of the COM-PARE PD DBS (Cognition and Mood in Parkinson disease STN vs GPi DBS) trial.
9 Forty-four patients with PD had complete data sets available to evaluate decisions for second-sided surgery. These data were approved by the University of Florida institutional review board, and consent was obtained from participants at the time of enrollment into the study. All patients with PD who undergo DBS implantation at the University of Florida (as standard procedure) begin with a unilateral operation (STN or GPi) and are then managed by medications and programming for 6 months (a minimum of once-a-month clinic appointments). Another date is reserved on the surgical schedule should a patient opt for second-sided implantation. All patients are offered a choice at 6 months whether to receive a second contralateral DBS implant in either the STN or GPi. We analyzed the UPDRS-III and dyskinesia scores (calculated as the sum of UPDRS-IV questions 32, 33, and 34) between groups, and we subcategorized the patients' decisions. These decisions were well documented by the clinician and were based on direct interview.
Six months postoperatively the groups were divided into those accepting (23 patients) and those declining (21 patients) a contralateral DBS implantation procedure. Reasons for their decisions were documented in the patients' charts during clinic visits. We reviewed the charts and subcategorized the patient's responses based on the categories in Tables 1 and 2 . The total motor UPDRS-III score was obtained and then broken down into subsets for left-and right-sided items (hand and leg rest tremor, postural tremor, upper-and lower-extremity rigidity, finger taps, hand movements, rapid alternating movements, and leg agility). Also, an asymmetry index was calculated to determine the degree of PD asymmetry in patients. This was calculated as (contralateral UPDRS-III score − ipsilateral UPDRS-III score)/contralateral UPDRS-III score × 100% and used baseline UPDRS-III scores. This calculation allowed for the assessment of PD symptoms for each hemibody.
Statistical Analysis
All data were analyzed using SAS version 9.1. First, descriptive statistics were obtained for the clinical variables, comparing those who chose bilateral DBS and those who chose to remain with unilateral implantation using the 2-sample t-test for continuous variables and the chi-square test for categorical variables. Second, a logistic regression model was fitted for the dichotomous outcome of receiving a second contralateral DBS, including the surgical site (STN vs GPi), laterality (right vs left), asymmetry in the baseline "off" medication UPDRS-III score, years with PD symptoms, and age at first surgery. The level of statistical significance was set at 0.05.
Results
This study carefully analyzed the reasons underpinning decisions for unilateral versus bilateral DBS placement in a randomized cohort of patients with PD. Interestingly, 21 (48%) of 44 patients opted to remain with unilateral DBS, and of these, 14 (67%) had a GPi target. The most common reason for adding a second side was the inadequacy to address motor symptoms (as determined by the patient and confirmed by interview). Dyskinesias, on/off motor fluctuations, and gait problems encompassed the most common reasons cited by patients for adding a second lead ( Table 1 ). All patients (21) declining bilateral DBS leads were documented to be pleased with the unilateral motor management of their PD symptoms ( Table 2) . Some of the patients also had other reasons influencing their decisions, but these represented a small percentage of the group ( Table 2) .
Examination of the charts beyond 1 year revealed that 2 (10%) of 21 patients who initially declined a second DBS lead later requested a second implantation (819 and 713 days after baseline). This represented 1 (4%) of 23 patients undergoing GPi DBS and 1 (5%) of 21 patients undergoing STN DBS (1 [4%] of 27 left-sided leads and 1 [6%] of 17 right-sided leads). Some patients with unilateral DBS have been successfully treated as long as 5 years. The mean follow-up for the unilateral cohort to date has been 3.5 years (1284 days).
The study population had a mean age of 59.8 ± 7.6 years (± SD) and a mean duration of symptoms of 12.2 ± 3.9 years (± SD). Distributions of these variables were approximately the same for those who chose a second DBS implantation and for those who opted to remain with unilateral implantation. Motor functions, as measured by UPDRS-III score, revealed that those who chose a second DBS procedure had significantly higher scores at baseline (total scores [p = 0.036] and/or higher ipsilateral scores [p = 0.002]), and a significantly lower asymmetry index (Table 3 ). In addition, the logistic regression analysis revealed that the odds of receiving bilateral STN DBS were 5.2 times higher than GPi DBS (Table 4) . Also, the greater the difference between the contralateral and the ipsilateral off-medication UPDRS-III baseline score, the less likely that bilateral DBS would be sought. For each 1% increase in asymmetry in the baseline off-medication UPDRS-III score, the odds of receiving bilateral DBS decreased by a factor of 0.96.
Discussion
Findings from this cohort of patients reveal that unilateral DBS satisfactorily improves motor symptoms in many patients with advanced PD, decreasing the risk involved with having a secondary DBS device. Those patients with a higher asymmetry index seem to benefit the most with only one device. Indeed, examination of the charts beyond this 1-year window revealed that 2 (10%) of 21 patients who initially declined a second DBS lead later requested a second implantation. This represented 1 (4%) of 23 patients with GPi DBS and 1 (5%) of 21 with STN DBS (1 [4%] of 27 left-sided leads and 1 [6%] of 17 right-sided leads). These patients received their second lead approximately 2 years after the first (819 and 713 days, respectively). The remaining patients in the cohort with unilateral implantation continue to be managed successfully, and some of the patients have had DBS for as long as 5 years. The mean follow-up for the unilateral cohort to date has been 3.5 years (1284 days). These data provide preliminary support that in at least a subset of patients, PD can be managed with unilateral DBS for longer than 1 year. This study raises important questions as to why twice as many patients who opted to remain with unilateral implantation were in the randomly assigned GPi group. A recent published examination of the NIH COMPARE data revealed a more robust improvement in quality of life for GPi DBS. 17 Additionally, it is known that greater medication reduction tends to occur with STN DBS than with GPi DBS. Medication is also more often reduced in bilateral than in unilateral procedures. Whereas the STN is thought to achieve its dyskinesia reduction as a result of medication, the GPi has been described as a direct dyskinesia suppressor. Patients undergoing unilateral GPi DBS may therefore be able to suppress dyskinesia and improve motor symptoms contralaterally, while also possibly being able to sustain or to even increase medication doses to address the ipsilateral body symptoms. This scenario contrasts with the typical implantation of DBS leads in the STN unilaterally, where medication reduction may be required to decrease severe dyskinesia and may ultimately render the individual suffering PD "off" on their ipsilateral (not surgically addressed) side. Therefore, one might hypothesize that unilateral GPi DBS may be superior in select cases, and particularly in cases of severe unilateral dyskinesia. The 14 patients who opted to remain with unilateral GPi implantation had lower total UPDRS-III motor scores and higher dyskinesia scores at baseline than the 9 GPi patients who later underwent bilateral implantation. These data may begin to provide some important insight into the relationship between dyskinesia and unilateral GPi DBS management. It is possible that larger sample sizes may distinguish whether dyskinesia and asymmetry may be the most important factors in dictating the overall adequacy of unilateral DBS.
Dyskinesia was cited frequently as one of the inadequately addressed motor symptoms by 8 (35%) of 23 patients in the group who later underwent bilateral implantation. Interestingly, 17 (81%) of 21 of those in the unilateral group had preoperative dyskinesia, but they expressed that unilateral DBS addressed their dyskinesia. In a previous study, unilateral STN DBS was shown to reduce dyskinesia in both duration and severity, while bilateral STN DBS did not offer dyskinesia improvement over unilateral implantation. 3, 5, 13 (This study failed to make the argument for the superiority of unilateral DBS during the best on-medication and on-DBS state.) This study, however, was small, and the experience from our data would argue for the use of a unilateral lead in most patients, and this would leave management with a second lead for a subset of patients, especially those with severe preoperative dyskinesia.
Insufficient improvement in gait was cited by 5 (22%) of 23 patients in our cohort, and these patients opted for placement of a second DBS lead. Three of these patients experienced improved quality of gait in their opinion, particularly stating improvements in their freezing and walking, although the UPDRS scores only showed an average decrease of 0.25 points for gait among these patients. The 2 remaining patients had no additional improvements. Those with gait improvement, however, clinically had levodopa-resistant postural and gait abnormalities as part of their presentation. Interestingly, unilateral STN DBS has been shown to improve gait in select patients; however, most studies document bilateral STN DBS also as an appropriate treatment for many aspects of gait. 2, 3, 5, 7, 15 Our data revealed that select patients with PD and severe gait dysfunction may not achieve sufficient gait improvement with unilateral DBS. Patients with asymmetrical UPDRS scores and less severe gait dysfunction may thus be better suited for unilateral DBS management, while those presenting with gait as a primary concern may require bilateral DBS. The clinician should keep in mind that gait dysfunction must respond preoperatively to a suprathreshold dose of levodopa for a second lead to have the chance to further improve gait symptoms. 10, 12 For this reason, unilateral and/or bilateral DBS may therefore be an inappropriate treatment for some patients seeking DBS for relief of gait/balance issues. Caution should be exercised if patients desire improvements in balance, as balance is not a symptom that clearly responds to levodopa and to DBS.
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Unilateral DBS may offer a less morbid alternative to bilateral procedures, which have risks particularly when treating the elderly. 5, 14 Bilateral procedures are associated with a greater risk of speech/verbal fluency related complications. 5 One could therefore make a risk-benefit ratio argument for selecting certain patients for unilateral procedures.
A current review of the literature does not clearly elucidate why some patients choose to remain with unilateral DBS. Unfortunately, there are limited data comparing patients' impressions with standard, objective measures of efficacy of PD management, making it ultimately challenging to compare results across studies. Unilateral DBS has been shown to reveal measurable reductions in the motor symptoms of PD in the ipsilateral hemibody; however, the greatest benefit has been evident in the contralat eral hemibody. 3, 8, 13, 16 Many studies are in agreement that some patients with PD are appropriately treated with only unilateral DBS. 3, 5, 8, 14, 16 However, in a staged DBS study, Samii et al. 13 found that most patients with PD were more appropriately treated with bilateral DBS. Germano et al. 5 found that of 12 patients treated, all of whom were considered candidates for bilateral DBS, 10 patients were adequately managed with unilateral DBS and only 2 patients required bilateral procedures. Similarly, Linazasoro et al. 8 found that in 8 patients who received unilateral DBS, only 3 patients required a second device. Walker et al. 16 also found that unilateral STN DBS was a reasonable option for treatment of moderate to advanced PD, with some patients in their series adequately managed after 12 months. There were several limitations in this study. The study was retrospective and involved reviewing clinician notes, although an important strength of the study was that the patients were drawn from a prospectively acquired data set with well-documented follow-up, and the decisions were derived from personal interviews. These patients were all closely observed each month post-DBS implantation, and detailed discussions and chart notes documented decisions regarding bilateral versus unilateral DBS. While the decision to remain with unilateral implantation was not randomized, most experts agree that patients with PD who have suboptimal outcomes will almost always choose second-sided DBS. This study was limited by a relatively small sample size that limited statistical comparisons between unilateral and bilateral groups. The motor raters in the study were not blinded to the side of the DBS implant, and the patients were not blinded to the location of the implant once the original COMPARE study was unblinded (in the GPi or STN). Another important limitation of the study was that the patients' experience after unilateral DBS may have introduced individual bias, in their opinions, concerning improvements and rationale for either declining or proceeding to bilateral DBS. Having suffered from PD for many years, some patients may be prone to exaggerate the impact of their improvement. Paradoxically, one could argue that extreme improvement after unilateral DBS is just as strong an argument for bilateral DBS as it is for opting to remain with unilateral DBS. A patient who has dramatic improvement after unilateral DBS may believe that a second DBS could offer similar improvement, and thus decide to proceed to bilateral implantation. It is important to note that all patients opting to remain with unilateral implantation stated that sufficient relief in symptoms was a factor in their decision to forgo a second DBS procedure. Interpretation of dyskinesia is limited because only elements of the UPDRS-IV were used to investigate these symptoms without extra, more accurate confirmation from other dyskinesia indices. Furthermore, for patients who elected to undergo bilateral surgery, the baseline UPDRS-III motor score was 7.5 points higher than in those who declined surgery, and this may have been a factor that influenced their overall decision. It is difficult to fully assess patients' fear of the actual surgery in this cohort as patients with severe anxiety may have been excluded in the preoperative screening process.
Conclusions
Our data revealed that many patients with advanced PD can be appropriately treated using unilateral DBS. There was a strong association between the degree of asymmetry in each patient's PD and the preference for unilateral DBS. Patients with asymmetrical PD should at the very least consider the option of a staged DBS operation, which in select cases may save the morbidity and expense of a second procedure. A second procedure can always be offered for insufficient benefit. Additionally and interestingly, in our cohort, patients undergoing DBS to the GPi were more likely to prefer unilateral DBS. The factor that most likely prompted bilateral surgery was the presence of higher total UPDRS-III scores. Therefore, patients with high UPDRS-III scores, more symmetric PD, severe gait dysfunction, or dyskinesia may in future studies prove to be the most likely to require bilateral surgery. For patients not meeting these descriptions, it is likely that unilateral DBS will provide meaningful benefit. Further larger studies will be required to fully elucidate the factors that may differentiate patients with PD who are candidates for unilateral from those who are candidates for bilateral DBS.
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